Emergent BioSolutions downgraded by JP Morgan with a new price target
$EBS
Biotechnology: Pharmaceutical Preparations
Health Care
JP Morgan downgraded Emergent BioSolutions from Neutral to Underweight and set a new price target of $9.00 from $23.00 previously